Clinical Trial Update: ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating ST-001 nanoFenretinide in relapsed or refractory small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• ST-001 nanoFenretinide (fenretinide)

Snippet

Sponsor: SciTech Development, Inc. | Conditions: Small Cell Lung Cancer | Phase 1 | Status: RECRUITING